vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Zedge, Inc. (ZDGE). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $7.6M, roughly 1.2× Zedge, Inc.). Zedge, Inc. runs the higher net margin — 10.4% vs -234.3%, a 244.6% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 5.8%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -1.0%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Zedge is a content distribution platform that provides consumers with a way to personalize their mobile devices. It has offices in Trondheim, Vilnius, and New York City.
FHTX vs ZDGE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $7.6M |
| Net Profit | $-21.7M | $788.0K |
| Gross Margin | — | — |
| Operating Margin | -258.2% | 12.0% |
| Net Margin | -234.3% | 10.4% |
| Revenue YoY | 223.8% | 5.8% |
| Net Profit YoY | -11.1% | 332.4% |
| EPS (diluted) | $-0.35 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $7.6M | ||
| Q3 25 | $8.2M | $7.5M | ||
| Q2 25 | $7.6M | $7.8M | ||
| Q1 25 | $6.0M | $7.0M | ||
| Q4 24 | $2.9M | $7.2M | ||
| Q3 24 | $7.8M | $7.6M | ||
| Q2 24 | $6.9M | $7.7M | ||
| Q1 24 | $5.0M | $7.8M |
| Q4 25 | $-21.7M | $788.0K | ||
| Q3 25 | $-15.8M | $-559.0K | ||
| Q2 25 | $-17.9M | $185.0K | ||
| Q1 25 | $-18.8M | $-1.7M | ||
| Q4 24 | $-19.5M | $-339.0K | ||
| Q3 24 | $-19.1M | $-39.0K | ||
| Q2 24 | $-23.0M | $113.0K | ||
| Q1 24 | $-25.0M | $-9.2M |
| Q4 25 | -258.2% | 12.0% | ||
| Q3 25 | -226.9% | -9.6% | ||
| Q2 25 | -279.2% | 2.1% | ||
| Q1 25 | -385.0% | -31.8% | ||
| Q4 24 | -840.5% | -6.4% | ||
| Q3 24 | -305.5% | -0.8% | ||
| Q2 24 | -386.6% | -1.7% | ||
| Q1 24 | -558.3% | -153.5% |
| Q4 25 | -234.3% | 10.4% | ||
| Q3 25 | -194.4% | -7.5% | ||
| Q2 25 | -237.3% | 2.4% | ||
| Q1 25 | -316.4% | -24.1% | ||
| Q4 24 | -682.9% | -4.7% | ||
| Q3 24 | -244.9% | -0.5% | ||
| Q2 24 | -333.6% | 1.5% | ||
| Q1 24 | -495.4% | -118.8% |
| Q4 25 | $-0.35 | $0.06 | ||
| Q3 25 | $-0.25 | $-0.04 | ||
| Q2 25 | $-0.28 | $0.01 | ||
| Q1 25 | $-0.30 | $-0.12 | ||
| Q4 24 | $-0.23 | $-0.02 | ||
| Q3 24 | $-0.31 | $0.00 | ||
| Q2 24 | $-0.45 | $0.01 | ||
| Q1 24 | $-0.59 | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $18.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $25.9M |
| Total Assets | $198.1M | $36.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $18.5M | ||
| Q3 25 | $89.3M | $18.6M | ||
| Q2 25 | $72.6M | $20.4M | ||
| Q1 25 | $61.0M | $20.1M | ||
| Q4 24 | $55.5M | $20.2M | ||
| Q3 24 | $57.7M | $20.0M | ||
| Q2 24 | $138.9M | $19.9M | ||
| Q1 24 | $79.3M | $18.1M |
| Q4 25 | $-108.5M | $25.9M | ||
| Q3 25 | $-89.7M | $25.9M | ||
| Q2 25 | $-76.7M | $28.6M | ||
| Q1 25 | $-61.7M | $28.2M | ||
| Q4 24 | $-45.5M | $30.1M | ||
| Q3 24 | $-28.3M | $30.9M | ||
| Q2 24 | $-14.3M | $30.9M | ||
| Q1 24 | $-97.5M | $30.7M |
| Q4 25 | $198.1M | $36.0M | ||
| Q3 25 | $205.0M | $35.7M | ||
| Q2 25 | $226.2M | $37.8M | ||
| Q1 25 | $258.7M | $37.1M | ||
| Q4 24 | $284.0M | $38.2M | ||
| Q3 24 | $308.4M | $38.2M | ||
| Q2 24 | $328.6M | $38.1M | ||
| Q1 24 | $255.0M | $37.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $825.0K |
| Free Cash FlowOCF − Capex | — | $808.0K |
| FCF MarginFCF / Revenue | — | 10.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $825.0K | ||
| Q3 25 | $-18.9M | $674.0K | ||
| Q2 25 | $-21.0M | $870.0K | ||
| Q1 25 | $-24.0M | $708.0K | ||
| Q4 24 | $-24.5M | $1.2M | ||
| Q3 24 | $-21.0M | $695.0K | ||
| Q2 24 | $-25.5M | $2.3M | ||
| Q1 24 | $-29.3M | $1.6M |
| Q4 25 | — | $808.0K | ||
| Q3 25 | — | $640.0K | ||
| Q2 25 | $-21.0M | $851.0K | ||
| Q1 25 | $-24.0M | $689.0K | ||
| Q4 24 | $-25.0M | $1.2M | ||
| Q3 24 | $-21.3M | $683.0K | ||
| Q2 24 | $-25.6M | $2.3M | ||
| Q1 24 | $-29.4M | $1.6M |
| Q4 25 | — | 10.6% | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | -278.2% | 11.0% | ||
| Q1 25 | -403.2% | 9.9% | ||
| Q4 24 | -875.3% | 16.1% | ||
| Q3 24 | -273.0% | 9.0% | ||
| Q2 24 | -371.0% | 30.4% | ||
| Q1 24 | -583.1% | 20.0% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.3% | 0.2% | ||
| Q1 25 | 0.5% | 0.3% | ||
| Q4 24 | 16.8% | 0.2% | ||
| Q3 24 | 4.0% | 0.2% | ||
| Q2 24 | 0.2% | 0.2% | ||
| Q1 24 | 2.0% | 0.0% |
| Q4 25 | — | 1.05× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 20.73× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHTX
Segment breakdown not available.
ZDGE
| Zedge Marketplace | $7.1M | 94% |
| Other | $468.0K | 6% |
